What is BCMA CAR-T therapy and how does it treat amyloidosis?

BCMA CAR-T therapy targets a protein found on the abnormal plasma cells responsible for producing the amyloid protein deposits. By targeting and eliminating these cells, it aims to stop further amyloid buildup and allow organ function to stabilize or improve over time.

Is CAR-T safe for patients with cardiac amyloidosis and heart failure?

It requires very careful risk assessment, since CAR-T's potential side effects can be harder for a compromised heart to tolerate. As this case shows, with close multidisciplinary monitoring, some patients with significant cardiac involvement can safely receive treatment. Eligibility should be assessed individually by a specialist team.

How can international patients access BCMA CAR-T therapy for amyloidosis in China?

Access typically starts with a case review, where medical records, imaging, and prior treatment history are submitted for evaluation. ChinaCureLink coordinates this process and helps match patients with hospitals experienced in this still-rare treatment approach.

top of page

ChinaCurelink
a MedeboundHEALTH Company

FREE CONSULTATION

Only 2 Cases in Medical Literature: How BCMA CAR-T Treated Cardiac Amyloidosis in China

ChinaCureLink

Tue Sep 01 2026

5 min read

Widget Didn’t Load

Check your internet and refresh this page.

If that doesn’t work, contact us.

bottom of page